Holders — by stockHoldings — by fund
Foresite Capital Management VI LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0002013341
$642.6M
disclosed book value
23
positions
26.2%
largest position share
Positions, as of 2026-06-30
top 23 of 23 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | CGONCG Oncology, Inc. | 2.4M | $168.4M | 26.2% |
| 2 | ALMSALUMIS INC. | 4.2M | $119.5M | 18.6% |
| 3 | SPTXSeaport Therapeutics, Inc. | 1.8M | $38.7M | 6% |
| 4 | DNLIDenali Therapeutics Inc. | 1.4M | $35.9M | 5.6% |
| 5 | CLDXCelldex Therapeutics, Inc. | 879,713 | $32.7M | 5.1% |
| 6 | AGIOAGIOS PHARMACEUTICALS, INC. | 785,000 | $29.1M | 4.5% |
| 7 | CRVSCorvus Pharmaceuticals, Inc. | 1.8M | $27.4M | 4.3% |
| 8 | PBLSParabilis Medicines, Inc. | 999,044 | $27.3M | 4.3% |
| 9 | GH Research PLC | 940,493 | $25.3M | 3.9% |
| 10 | JBIOJade Biosciences, Inc. | 886,667 | $19.7M | 3.1% |
| 11 | HNGEHinge Health, Inc. | 220,400 | $18.3M | 2.8% |
| 12 | KYMRKymera Therapeutics, Inc. | 146,332 | $16.8M | 2.6% |
| 13 | ATAIAtaiBeckley Inc. | 2.8M | $14.5M | 2.3% |
| 14 | VSTMVerastem, Inc. | 3.1M | $12.0M | 1.9% |
| 15 | BEAMBeam Therapeutics Inc. | 330,000 | $11.3M | 1.8% |
| 16 | NERVMinerva Neurosciences, Inc. | 2.0M | $11.0M | 1.7% |
| 17 | AVBPArriVent BioPharma, Inc. | 301,341 | $10.5M | 1.6% |
| 18 | AURAAura Biosciences, Inc. | 1.3M | $9.5M | 1.5% |
| 19 | CRNXCrinetics Pharmaceuticals, Inc. | 212,010 | $7.9M | 1.2% |
| 20 | Research Alliance Corp III | 300,000 | $3.2M | 0.5% |
| 21 | Zura Bio Ltd | 450,000 | $2.7M | 0.4% |
| 22 | KLRAKailera Therapeutics, Inc. | 37,500 | $826,125 | 0.1% |
| 23 | IRONDisc Medicine, Inc. | 970 | $70,946 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.